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Edited by Laszlo NagyAbstract Aggrecanases that include ADAMTS1, 4, 5, 8, 9 and
15 are considered to play key roles in aggrecan degradation in
osteoarthritic cartilage. Here we demonstrate that calcium pen-
tosan polysulfate (CaPPS) directly inhibits the aggrecanase
activity of ADAMTS4 without aﬀecting the mRNA expression
of the ADAMTS species in interleukin-1a-stimulated osteoar-
thritic chondrocytes. Synthetic peptides corresponding to speciﬁc
regions of the thrombospondin type 1 repeat, cysteine-rich or
spacer domain of ADAMTS4 inhibit the binding to immobilized
CaPPS. These data suggest that CaPPS could function as chon-
droprotective agent for the treatment of osteoarthritis by inhibi-
tion of ADAMTS4 through interaction with the C-terminal
ancillary domain.
 2008 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Osteoarthritis (OA) is the most common form of arthritis
and characterized by loss of articular cartilage, which is as-
cribed mainly to proteolysis of the structural components of
the extracellular matrix, i.e., proteoglycans and collagens [1].
Accumulated lines of evidence have indicated that aggrecanas-
es play a central role in degradation of aggrecan, the major
proteoglycan in cartilage, by cleaving at Glu-X bonds includ-
ing the Glu392–Ala393 bond [1,2]. These proteinases belong to
the ADAMTS (a disintegrin and metalloproteinase with
thrombospondin motifs) gene family, and ADAMTS1, 4, 5,
8, 9 and 15 are known to exhibit the signature aggrecanase
activity (cleavage at the Glu392–Ala393 bond) [1,2]. Recent
studies using ADAMTS4 (also called aggrecanase-1) and
ADAMTS5 (aggrecanase-2) knockout mice have indicated
that ADAMTS5 is responsible for cartilage destruction by
aggrecan degradation in mice [3,4]. In human chondrocytes,
however, ADAMTS4 is the aggrecanase induced by treatment
with cytokines such as interleukin-1 (IL-1), whereas the
ADAMTS5 expression is constitutive [5–7]. Our recent study
on the expression of ADAMTS1, 4, 5, 8, 9 and 15 demon-
strated that ADAMTS4 is selectively over-expressed in human*Corresponding author. Fax: +81 3 3353 3290.
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doi:10.1016/j.febslet.2008.07.036OA cartilage and correlates directly with the extent of cartilage
destruction, whereas ADAMTS5 is constitutively expressed
[8]. Thus, it seems likely that ADAMTS4 is the major aggre-
canase responsible for initial aggrecan proteolysis in human
OA cartilage.
Calcium pentosan polysulfate (CaPPS) exhibits chondropro-
tective eﬀects in experimental animal models of OA, and is
used as a veterinary drug for animal OA [9,10]. It is also under
clinical trials for human OA. Previous in vitro studies have
shown to suppress release of aggrecan fragments from explant
cultures of bovine articular cartilage [11,12]. However, these
studies failed to describe the eﬀects of CaPPS on mRNA
expression of aggrecanases in OA chondrocytes, nor demon-
strate the inhibitory activity of this agent on ADAMTS spe-
cies. In this report, we provide the ﬁrst evidence that CaPPS
suppresses the aggrecanase activity through direct inhibition
of ADAMTS4 by binding to its C-terminal ancillary domains
but not the mRNA expression of the ADAMTS species.2. Materials and methods
2.1. Materials
Recombinant human full-length ADAMTS4 and its C-terminus-
truncated mutants, i.e., DSp lacking the spacer (Sp) domain, DCR/Sp
lacking most of the cysteine-rich (CR) domain and the Sp domain and
DTS/CR/Sp lacking the thrombospondin type 1 repeat (TS), CR and
Sp domains were puriﬁed as described previously [13]. CaPPS and tissue
inhibitor of metalloproteinases-3 (TIMP-3) were provided by Arthrop-
harm (Sydney, New SouthWales, Australia) andDaiichi Fine Chemical
Co. Ltd. (Takaoka, Japan), respectively.
2.2. Chondrocyte cultures
Chondrocytes were isolated from articular cartilage obtained at
arthroplasty from knee or hip joints of OA patients and cultured in
Dulbeccos modiﬁed Eagles medium/Hams F-12 (DMEM/F-12)
(Invitrogen Corp., Carlsbad, CA) supplemented with 10% fetal bovine
serum, ascorbic acid and antibiotics [14]. For the experimental use of
the surgical samples, informed consent was obtained from the patients
according to the Hospital ethical guidelines.
2.3. Inhibition of signature aggrecanase activity in cultured chondrocytes
and cartilage with CaPPS
Chondrocytes were serum-starved in DMEM/F-12 containing 0.2%
lactalbumin hydrolysate and treated with IL-1a (1 ng/ml) (Dainippon-
Sumitomo Pharmaceutical Company Ltd., Osaka, Japan) and CaPPS
(0, 0.1, 1 and 10 lg/ml) for 5 days in the presence of porcine aggrecan
(100 lg/ml). The concentratedmedia were subjected to SDS–PAGE after
deglycosylation and transferred onto PVDF membranes [13,15]. Aggre-
canase activity was evaluated by immunoblotting with anti-NITEGE392
neoepitope antibody (2 lg/ml) [13]. Similarly, explants of osteoarthritic
cartilage (2 · 2 · 2 mm) were cultured for 3 days in 24-well platesation of European Biochemical Societies.
Fig. 1. Inhibition of signature aggrecanase activity in OA chondro-
cytes and cartilage with CaPPS. (A) OA chondrocytes were cultured in
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hydrolysate in the absence or presence of IL-1a (1 ng/ml) and CaPPS
(0, 0.1, 1 and 10 lg/ml). Cartilage tissues collected from each well were
freeze-milled under liquid nitrogen into a ﬁne powder, from which prote-
oglycans were extracted with 4 M guanidine hydrochloride, 10 mM
EDTA, 1 M amino caproic acid, 50 mM sodium acetate, pH 6.8. Super-
natants of the extracts were deglycosylated with chondroitinase ABC
and keratanase (Seikagaku Corporation, Tokyo, Japan) and subjected
to immunoblotting with anti-NITEGE392 neoepitope antibody.
2.4. Screening of mRNA expression of ADAMTS species by RT-PCR
Total RNA was extracted from the chondrocytes treated with or
without IL-1a (1 ng/ml) and CaPPS (0, 0.1, 1 and 10 lg/ml) for 18 h
and reverse-transcribed to cDNA using SuperScript II reverse trans-
criptase (Life Technologies, Rockville, MD). The cDNAs were ampli-
ﬁed by PCR with primers speciﬁc to ADAMTS1, 4, 5, 8, 9 and 15 and
housekeeping gene glyceraldehydes-3-phosphate dehydrogenase
(GAPDH) as described previously [8].
2.5. Immunoblotting of ADAMTS4
Chondrocytes were cultured for 5 days under the serum-free condi-
tions, and the concentrated media were subjected to SDS–PAGE under
reduction and immunoblotted with anti-ADAMTS4 antibody (0.5 lg/
ml; 250-4F7) [8].
2.6. Inhibition of ADAMTS4 aggrecanase activity with CaPPS
Recombinant ADAMTS4 and DSp (10 nM) [13] were treated with
CaPPS (0, 0.1, 0.3, 1, 3, 10, 30 and 100 lg/ml) or TIMP-3 (100 nM)
for 30 min at 37 C and then incubated with aggrecan (2 mg/ml) for
16 h at 37 C. After deglycosylation, the signature aggrecanase activity
was monitored by immunoblotting using the anti-NITEGE392 neoepi-
tope antibody [13,15]. Densitometrical analysis of the immunoreactive
bands was performed by scanning densitometry using Scion Image
(Scion Corp., Frederick, MD). IC50 values (concentration at 50% inhi-
bition) were estimated by a scientiﬁc graphing and analytical software
Origin 7.0 (Origin Lab Corp., Northampton, MA). We also carried out
immunoblotting analysis for the above-mentioned samples using anti-
SELE1564 neoepitope antibody (5 lg/ml) [16], which was kindly
provided by Dr. Amanda J. Fosang (Department of Paediatrics and
Murdoch Childrens Research Institute, University of Melbourne,
Melbourne, Australia).
2.7. Binding of ADAMTS4 to immobilized CaPPS
Solid-phase binding assay was performed by incubating 125I-labeled
ADAMTS4, DSp, DCR/Sp, DTS/CR/Sp [13] or bovine serum albumin
(BSA) in CaPPS-coated wells, which were prepared by reacting strepto-
avidin-coated microplates with 1 mg/ml biotinylated CaPPS, followed
by washing with 50 mM Tris–HCl buﬀer, pH 7.5, 0.15 M NaCl,
10 mM CaCl2, 0.05% Brij-35 and subsequent blocking with 3% Block-
Ace (Dainippon-Sumitomo Pharmaceutical Company Ltd., Osaka,
Japan). For inhibition study, the microplates were incubated with syn-
thetic peptides (0.25, 0.5, 1 and 3 mg/ml) corresponding to heparin bind-
ing region in the TS domain of ADAMTS4 (GGWGPWGPWGD531),
the glycosaminoglycan binding region in the CR domain (GSKKKF-
DKCM676), a part in the CR and Sp domains (SFRKFRYG698), a part
in the Sp domain (LRRRPWAGRK837) or RASCETP (a negative con-
trol) for 1 h at 23 C prior to the binding assay. Reaction was continued
by adding 125I-labeled ADAMTS4 or BSA (2 · 105 cpm/well, 10 ng/
well each) for 24 h at 4 C. Binding activity of 125I-labeled ADAMTS4
species andBSA toCaPPSwas determined by calculating the ratios (per-
centage) of radioactivity bound to CaPPS on the wells to total counts
added using a c-counter.
2.8. Statistical analysis
Comparisons against control were performed by Dunnetts multiple
comparison test. P values less than 0.05 were considered signiﬁcant.
the absence or presence of IL-1a and CaPPS in serum-free DMEM/F-
12 containing porcine aggrecan. Aggrecanase activity was evaluated by
immunoblotting with anti-NITEGE392 neoepitope antibody. (B)
Explants of OA cartilage were cultured in the absence or presence of
IL-1a and CaPPS in serum-free DMEM/F-12 and aggrecanase activity
was determined by immunoblotting of proteoglycans extracted from
the cartilage. Arrows indicate the fragments immunoreactive with anti-
NITEGE392 antibody.3. Results and discussion
OA chondrocytes showed weak signature aggrecanase activ-
ity under non-stimulated conditions. The activity was in-creased in the chondrocytes treated with IL-1a, and it was
decreased in a dose-dependent manner by the treatment with
CaPPS (Fig. 1A). Similarly, CaPPS dose-dependently inhibited
the signature aggrecanase activity in OA cartilage tissue, which
was stimulated with IL-1a (Fig. 1B). To study the eﬀect of
CaPPS on the expression of aggrecanases, we examined the
mRNA expression of ADAMTS1, 4, 5, 8, 9 and 15 in IL-1a-
stimulated OA chondrocytes by RT-PCR. As shown in Fig.
2A, the expression of ADAMTS4 appeared to be stimulated
with IL-1a, but ADAMTS1, ADAMTS5 and ADAMTS9
were constitutively expressed. The expression of ADAMTS15
was decreased after the IL-1a stimulation and ADAMTS8
was negligibly expressed before or after treatment with IL-
1a. Importantly, the expression of all these ADAMTS species
in IL-1a-stimulated chondrocytes was not changed by the
treatment with diﬀerent concentrations of CaPPS (Fig. 2A).
Real-time PCR conﬁrmed these data (data not shown). In ac-
cord with the mRNA data, the production level of ADAMTS4
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ment, but CaPPS did not aﬀect the level (Fig. 2B).
In the next experiment, we examined whether CaPPS di-
rectly inhibits the signature aggrecanase activity of recombi-
nant full-length ADAMTS4 and its deletion mutant DSp,
both of which exhibit aggrecanase activity [13]. As shown in
Fig. 3A, density of the immunoreactive aggrecan fragment
produced by the action of the ADAMTS4 species decreased
in a dose-dependent manner by the CaPPS treatment. The den-
sitometrical analysis of the bands indicated that IC50 values of
ADAMTS4 and DSp are 0.2 and 2.4 lg/ml, respectively (Fig.
3B). When the eﬀect of CaPPS on the ADAMTS4 aggrecanase
activity against one of the chondroitin sulfate-2 sites was
examined by immunoblotting with anti-SELE1564 neoepitope
antibody, the activity was dose-dependently inhibited (Fig.
3C). These data demonstrate for the ﬁrst time that CaPPS
has no impact on the gene expression of ADAMTS1, 4, 5, 8,Fig. 2. Eﬀects of CaPPS on the mRNA expression of ADAMTS
species and production of ADAMTS4 protein in OA chondrocytes.
(A) The mRNA expression of ADAMTS1, 4, 5, 8, 9 and 15 was
examined by RT-PCR in the chondrocytes treated without or with IL-
1a and CaPPS. GAPDH is shown as a control for loaded samples. (B)
Immunoblotting analysis of the CaPPS eﬀects on the ADAMTS4
expression. Chondrocytes were cultured in the absence or presence of
IL-1a and CaPPS in serum-free DMEM/F-12 and conditioned media
were subjected to immunoblotting using monoclonal antibody to
ADAMTS4. Arrowhead indicates 58-kDa ADAMTS4.9 and 15 in OA chondrocytes, but does directly inhibit the agg-
recanase activity of puriﬁed recombinant ADAMTS4. We
have previously shown that CaPPS enhances production of
TIMP-3 at the posttranscriptional level in cultured rheumatoid
synovial ﬁbroblasts and OA chondrocytes [17]. Thus, CaPPS
not only inhibits aggrecanase activity of ADAMTS4 produced
by OA chondrocytes directly but also indirectly by increasing
levels of its inhibitor, TIMP-3.
Solid-phase binding assay showed that among 125I-labeled
ADAMTS4, DSp, DCR/Sp and DTS/CR/Sp, only ADAMTS4
and DSp exhibit binding activity to CaPPS (data not shown).
To further study the binding sites of ADAMTS4 to CaPPS,
we carried out inhibition study of the binding of ADAMTS4
to CaPPS with synthetic peptides and found that the binding
activity is inhibited by treatment with the peptides of
GGWGPWGPWGD531 corresponding to a part of the TS do-
main, GSKKKFDKCM676 to that of the CR domain andFig. 3. Direct inhibition of ADAMTS4 aggrecanase activity by
CaPPS. (A) Inhibition of signature aggrecanase activity of full-length
ADAMTS4 and DSp with CaPPS. The recombinant ADAMTS4
species were incubated with buﬀer alone (NC), CaPPS or TIMP-3, and
then reacted with aggrecan. After deglycosylation of the aggrecan
samples, they were subjected to immunoblotting with anti-NITEGE392
neoepitope antibody. (B) Inhibition curves of the ADAMTS4 activity
with CaPPS. Relative inhibition (%) of the signature aggrecanase
activity of ADAMTS4 and DSp with CaPPS was calculated by
densitometrical analysis of the bands. (C) Inhibition of the ADAMTS4
aggrecanase activity to the chondroitin sulfate-2 site with CaPPS.
ADAMTS4 incubated with buﬀer alone (NC), CaPPS or TIMP-3 was
reacted with aggrecan, and then the samples were subjected to
immunoblotting with anti-SELE1564 neoepitope antibody.
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(Fig. 4). However, no inhibition was observed with SFRK-
FRYG698 corresponding to a part of the CR and Sp domains
or RASCETP (a negative control). These data suggest that
ADAMTS4 interacts with CaPPS at three sites of the TS,
CR and Sp domains.
TIMP-3 is considered to be the physiological inhibitor of
ADAMTS4 [15,18], and it is predictable that TIMP-3 inhibits
the activity of ADAMTS4 by binding to the catalytic site.
However, accumulated lines of evidence have demonstrated
that the non-catalytic C-terminal ancillary domains including
TS, CR and Sp domains play key roles in modulation of the
ADAMTS4 aggrecanase activity [13,19–21]. The binding of
the TS and Sp domains to aggrecan glycosaminoglycans is
known to enhance TIMP-3 inhibition of ADAMTS4 activity
[19], and we have previously demonstrated that ﬁbronectin
inhibits ADAMTS4 aggrecanase activity through its interac-
tion with the Sp domain [13]. The present results showing
the binding between CaPPS and the TS, CR and Sp domains
strongly suggest that the inhibition of ADAMTS4 by CaPPS
is ascribed to the hindrance of access of ADAMTS4 to aggre-
can, since these domains are required for the aggrecanase
activity of ADAMTS4 [13,21,22].
Since CaPPS is a heparin-like substance, heparin would also
be expected to have inhibitory activity to ADAMTS4. Indeed,
a recent study has shown that heparin inhibits the aggrecanase
activity of the full-length ADAMTS4 through binding to the
Sp domain [21]. However, the IC50 value of CaPPS to ADAM-
TS4 (0.2 lg/ml) is 23-fold lower than that of heparin (4.5 lg/
ml) [21], and CaPPS, but not heparin, can inhibit the aggrecan-Fig. 4. Inhibition of the ADAMTS4 binding to immobilized CaPPS
with synthetic peptides. Microplates coated with CaPPS were incu-
bated with 125I-labeled BSA or ADAMTS4 after incubation of the
microplates without or with the synthetic peptides corresponding to
the parts of the TS, CR or Sp domain of ADAMTS4 (see a lower panel
showing schematic presentation of the ADAMTS4 domains) or
RASCETP (a negative control). The radioactivity bound to CaPPS
was counted using a c-counter. Error bars indicate S.E. (n = 3).
*P < 0.05; **P < 0.01.ase activity of DSp through the interaction with the CR and TS
domain. ADAMTS4 is present mainly in a C-terminus-trun-
cated form, i.e. DSp, in pathological tissues including human
cartilage and synovial tissue [8,22], which may be elaborated
by the action of matrix metalloproteinases [23]. Thus, once
ADAMTS4 is processed to DSp, neither ﬁbronectin nor hepa-
rin can block the aggrecanase activity of DSp, but CaPPS is
still able to achieve inhibition. Pharmacokinetic studies in sev-
eral species have shown that within 4 h of intramuscular injec-
tions of 2–3 mg/kg of CaPPS plasma levels of 4–5 lg/ml are
generally observed [9]. An equine study also revealed that an
intramuscular dosage of 2 mg/kg CaPPS produced synovial
ﬂuid levels of 1–2 lg/ml over the same time period [24]. These
studies indicate that the concentration of CaPPS obtained in
synovial joints after administration of the recommended ther-
apeutic dose for the treatment of OA is within the range that
could achieve inhibition of ADAMTS4 activity in this com-
partment.
In animal models of OA, CaPPS has been shown to preserve
cartilage integrity, but it also exhibited other pharmacological
actions which could contribute to its chondroprotective activ-
ity [9,10]. Clinically, CaPPS [9] and the corresponding sodium
salt, NaPPS [25] have been shown to signiﬁcantly improve the
symptoms and functional index of joints in a double blind pla-
cebo controlled clinical trials with OA patients. Although the
observed improvement in joint symptoms may not reﬂect
any beneﬁcial of CaPPS on joint articular cartilage in the short
time frame used in these clinical trials, the present observations
of the ability of this agent to inhibit ADAMTS4 and increasing
TIMP-3 production [17] lend further support to the assign-
ment of this agent to the class of disease modifying drugs for
OA. However, additional longer-term clinical and cartilage
imaging studies will be required to conﬁrm this assignment.
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